The company was seeking its first approval from the agency to use the therapy to treat patients with severe Leukocyte Adhesion Deficiency-I (LAD-I), a disorder Rocket estimates impacts roughly 800 to 1,000 individuals in the U.S. and Europe.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ZB7iWyh
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment